In situ dose amplification by apoptosis-targeted drug delivery

Kai Wang, Moon Hee Na, Allan S. Hoffman, Gayong Shim, Su Eun Han, Yu Kyoung Oh, Ick Chan Kwon, In-San Kim, Byung Heon Lee

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

When tumor cells undergo apoptosis in response to chemotherapy, the levels of apoptotic biomarkers such as histone H1 are increased at the tumor. This would amplify in situ homing signals and thus drug delivery by apoptosis-targeted drugs. To examine this possibility, we prepared apoptosis-targeted liposomes containing doxorubicin by labeling them with the CQRPPR peptide (ApoPep-1) that recognizes apoptotic cells by binding to histone H1. ApoPep-1-labeled liposomes, but not folate-labeled liposomes, inhibited tumor growth in mice more efficiently than untargeted liposomes, although in vitro cytotoxicities of those liposomes were similar. Fluorescence imaging signals at tumor were increased by the homing of ApoPep-1-labeled, fluorescent liposomes, which was correlated with the increase of apoptosis and the amount of doxorubicin at the tumor and, conversely, with the decrease of tumor volume. These results demonstrate that the apoptosis-targeted drug delivery enables in situ dose amplification and, when combined with imaging of apoptosis, provides a real-time monitoring of treatment response for cancer theragnosis.

Original languageEnglish
Pages (from-to)214-217
Number of pages4
JournalJournal of Controlled Release
Volume154
Issue number3
DOIs
Publication statusPublished - 2011 Sep 25
Externally publishedYes

Fingerprint

Liposomes
Apoptosis
Pharmaceutical Preparations
Neoplasms
Histones
Doxorubicin
Optical Imaging
Tumor Burden
Folic Acid
Biomarkers
Drug Therapy
Peptides
cysteinyl-glutaminyl-arginyl-prolyl-prolyl-arginine
Growth

Keywords

  • Apoptosis
  • Drug delivery
  • Histone H1
  • In situ dose amplification
  • Theragnosis

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Wang, K., Na, M. H., Hoffman, A. S., Shim, G., Han, S. E., Oh, Y. K., ... Lee, B. H. (2011). In situ dose amplification by apoptosis-targeted drug delivery. Journal of Controlled Release, 154(3), 214-217. https://doi.org/10.1016/j.jconrel.2011.06.043

In situ dose amplification by apoptosis-targeted drug delivery. / Wang, Kai; Na, Moon Hee; Hoffman, Allan S.; Shim, Gayong; Han, Su Eun; Oh, Yu Kyoung; Kwon, Ick Chan; Kim, In-San; Lee, Byung Heon.

In: Journal of Controlled Release, Vol. 154, No. 3, 25.09.2011, p. 214-217.

Research output: Contribution to journalArticle

Wang, K, Na, MH, Hoffman, AS, Shim, G, Han, SE, Oh, YK, Kwon, IC, Kim, I-S & Lee, BH 2011, 'In situ dose amplification by apoptosis-targeted drug delivery', Journal of Controlled Release, vol. 154, no. 3, pp. 214-217. https://doi.org/10.1016/j.jconrel.2011.06.043
Wang, Kai ; Na, Moon Hee ; Hoffman, Allan S. ; Shim, Gayong ; Han, Su Eun ; Oh, Yu Kyoung ; Kwon, Ick Chan ; Kim, In-San ; Lee, Byung Heon. / In situ dose amplification by apoptosis-targeted drug delivery. In: Journal of Controlled Release. 2011 ; Vol. 154, No. 3. pp. 214-217.
@article{3fe162d8cb624d28b368d05ae2be0361,
title = "In situ dose amplification by apoptosis-targeted drug delivery",
abstract = "When tumor cells undergo apoptosis in response to chemotherapy, the levels of apoptotic biomarkers such as histone H1 are increased at the tumor. This would amplify in situ homing signals and thus drug delivery by apoptosis-targeted drugs. To examine this possibility, we prepared apoptosis-targeted liposomes containing doxorubicin by labeling them with the CQRPPR peptide (ApoPep-1) that recognizes apoptotic cells by binding to histone H1. ApoPep-1-labeled liposomes, but not folate-labeled liposomes, inhibited tumor growth in mice more efficiently than untargeted liposomes, although in vitro cytotoxicities of those liposomes were similar. Fluorescence imaging signals at tumor were increased by the homing of ApoPep-1-labeled, fluorescent liposomes, which was correlated with the increase of apoptosis and the amount of doxorubicin at the tumor and, conversely, with the decrease of tumor volume. These results demonstrate that the apoptosis-targeted drug delivery enables in situ dose amplification and, when combined with imaging of apoptosis, provides a real-time monitoring of treatment response for cancer theragnosis.",
keywords = "Apoptosis, Drug delivery, Histone H1, In situ dose amplification, Theragnosis",
author = "Kai Wang and Na, {Moon Hee} and Hoffman, {Allan S.} and Gayong Shim and Han, {Su Eun} and Oh, {Yu Kyoung} and Kwon, {Ick Chan} and In-San Kim and Lee, {Byung Heon}",
year = "2011",
month = "9",
day = "25",
doi = "10.1016/j.jconrel.2011.06.043",
language = "English",
volume = "154",
pages = "214--217",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - In situ dose amplification by apoptosis-targeted drug delivery

AU - Wang, Kai

AU - Na, Moon Hee

AU - Hoffman, Allan S.

AU - Shim, Gayong

AU - Han, Su Eun

AU - Oh, Yu Kyoung

AU - Kwon, Ick Chan

AU - Kim, In-San

AU - Lee, Byung Heon

PY - 2011/9/25

Y1 - 2011/9/25

N2 - When tumor cells undergo apoptosis in response to chemotherapy, the levels of apoptotic biomarkers such as histone H1 are increased at the tumor. This would amplify in situ homing signals and thus drug delivery by apoptosis-targeted drugs. To examine this possibility, we prepared apoptosis-targeted liposomes containing doxorubicin by labeling them with the CQRPPR peptide (ApoPep-1) that recognizes apoptotic cells by binding to histone H1. ApoPep-1-labeled liposomes, but not folate-labeled liposomes, inhibited tumor growth in mice more efficiently than untargeted liposomes, although in vitro cytotoxicities of those liposomes were similar. Fluorescence imaging signals at tumor were increased by the homing of ApoPep-1-labeled, fluorescent liposomes, which was correlated with the increase of apoptosis and the amount of doxorubicin at the tumor and, conversely, with the decrease of tumor volume. These results demonstrate that the apoptosis-targeted drug delivery enables in situ dose amplification and, when combined with imaging of apoptosis, provides a real-time monitoring of treatment response for cancer theragnosis.

AB - When tumor cells undergo apoptosis in response to chemotherapy, the levels of apoptotic biomarkers such as histone H1 are increased at the tumor. This would amplify in situ homing signals and thus drug delivery by apoptosis-targeted drugs. To examine this possibility, we prepared apoptosis-targeted liposomes containing doxorubicin by labeling them with the CQRPPR peptide (ApoPep-1) that recognizes apoptotic cells by binding to histone H1. ApoPep-1-labeled liposomes, but not folate-labeled liposomes, inhibited tumor growth in mice more efficiently than untargeted liposomes, although in vitro cytotoxicities of those liposomes were similar. Fluorescence imaging signals at tumor were increased by the homing of ApoPep-1-labeled, fluorescent liposomes, which was correlated with the increase of apoptosis and the amount of doxorubicin at the tumor and, conversely, with the decrease of tumor volume. These results demonstrate that the apoptosis-targeted drug delivery enables in situ dose amplification and, when combined with imaging of apoptosis, provides a real-time monitoring of treatment response for cancer theragnosis.

KW - Apoptosis

KW - Drug delivery

KW - Histone H1

KW - In situ dose amplification

KW - Theragnosis

UR - http://www.scopus.com/inward/record.url?scp=80052552063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052552063&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2011.06.043

DO - 10.1016/j.jconrel.2011.06.043

M3 - Article

VL - 154

SP - 214

EP - 217

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 3

ER -